Literature DB >> 25845022

VEGF and dual-EGFR inhibition in colorectal cancer.

Gerald S Falchook1, Razelle Kurzrock.   

Abstract

Entities:  

Year:  2015        PMID： 25845022      PMCID： PMC4614794          DOI： 10.1080/15384101.2015.1022071

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  Angiogenesis as a therapeutic target.

Authors:  Napoleone Ferrara; Robert S Kerbel
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

2.  Impact of EGFR expression on colorectal cancer patient prognosis and survival.

Authors:  J-P Spano; C Lagorce; D Atlan; G Milano; J Domont; R Benamouzig; A Attar; J Benichou; A Martin; J-F Morere; M Raphael; F Penault-Llorca; J-L Breau; R Fagard; D Khayat; P Wind
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

3.  Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development.

Authors:  Beate M Lichtenberger; Poi Kiang Tan; Heide Niederleithner; Napoleone Ferrara; Peter Petzelbauer; Maria Sibilia
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

4.  Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Authors:  Andrew J Weickhardt; Tim J Price; Geoff Chong; Val Gebski; Nick Pavlakis; Terrance G Johns; Arun Azad; Effie Skrinos; Kate Fluck; Alexander Dobrovic; Renato Salemi; Andrew M Scott; John M Mariadason; Niall C Tebbutt
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  Survival of cancer cells is maintained by EGFR independent of its kinase activity.

Authors:  Zhang Weihua; Rachel Tsan; Wei-Chien Huang; Qiuyu Wu; Chao-Hua Chiu; Isaiah J Fidler; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

6.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

7.  Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer.

Authors:  Gerald S Falchook; Aung Naing; Jennifer J Wheler; Apostolia M Tsimberidou; Ralph Zinner; David S Hong; Siqing Fu; Sarina A Piha-Paul; Filip Janku; Kenneth R Hess; Christel Bastida; Razelle Kurzrock
Journal:  Oncoscience       Date:  2014-08-07
  7 in total
  9 in total

1.  Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients.

Authors:  Hui Wang; Ming Zhan; Ruimeng Yang; Yongheng Shi; Qiang Liu; Jian Wang
Journal:  Cell Cycle       Date:  2018-09-22       Impact factor: 4.534

2.  Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.

Authors:  Chenbo Ding; Longmei Li; Taoyu Yang; Xiaobo Fan; Guoqiu Wu
Journal:  BMC Cancer       Date:  2016-10-12       Impact factor: 4.430

Review 3.  Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Authors:  Taxiarchis Konstantinos Nikolouzakis; Loukia Vassilopoulou; Persefoni Fragkiadaki; Theodoros Mariolis Sapsakos; Georgios Z Papadakis; Demetrios A Spandidos; Aristides M Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2018-03-21       Impact factor: 4.136

4.  Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.

Authors:  Yiran Tao; Ruixue Wang; Qinhuai Lai; Mengdan Wu; Yuxi Wang; Xiaohua Jiang; Lishi Zeng; Shijie Zhou; Zhongping Li; Tinghan Yang; Yuqin Yao; Yangping Wu; Lin Yu; Yuyin Fu; Weirong Lai; Yujia Peng; Ying Lu; Zhixiong Zhang; Cuiyu Guo; Guangbing Zhang; Lantu Gou; Jinliang Yang
Journal:  Mol Oncol       Date:  2019-07-22       Impact factor: 6.603

5.  Clinical value evaluation of serum markers for early diagnosis of colorectal cancer.

Authors:  Wen-Yue Song; Xin Zhang; Qi Zhang; Peng-Jun Zhang; Rong Zhang
Journal:  World J Gastrointest Oncol       Date:  2020-02-15

6.  Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells.

Authors:  Qin Li; Shun Zhang; Miao Hu; Ming Xu; Xiaohua Jiang
Journal:  Int J Mol Med       Date:  2019-11-26       Impact factor: 4.101

7.  A Combined four-mRNA Signature Associated with Lymphatic Metastasis for Prognosis of Colorectal Cancer.

Authors:  Xueping Li; Qiang Zhang; Lan Zhao; Longyang Jiang; Aoshuang Qi; Qian Wei; Xinyue Song; Lin Wang; Liwen Zhang; Yanyun Zhao; Xuemei Lv; Minjie Wei; Lin Zhao
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

8.  Zinc finger of the cerebellum 5 promotes colorectal cancer cell proliferation and cell cycle progression through enhanced CDK1/CDC25c signaling.

Authors:  Abuduzhayier Maimaiti; Abulaiti Aizezi; Jianati Anniwaer; Buhajar Ali; Mukadas Dilixiati
Journal:  Arch Med Sci       Date:  2019-11-11       Impact factor: 3.318

Review 9.  Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review.

Authors:  Gaia Peluso; Paola Incollingo; Armando Calogero; Vincenzo Tammaro; Niccolò Rupealta; Gaetano Chiacchio; Maria Laura Sandoval Sotelo; Gianluca Minieri; Antonio Pisani; Eleonora Riccio; Massimo Sabbatini; Umberto Marcello Bracale; Concetta Anna Dodaro; Nicola Carlomagno
Journal:  Biomed Res Int       Date:  2017-10-29       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.